Zomedica Corp. (ZOMDF) stock
ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Zomedica profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Zomedica's profit margin for the twelve months ending Sep 30, 2026 was -41.4%. For fiscal 2025 it was -255.6%, against -172.2% the year before. The highest annual figure on record is -89.9% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -255.6% | −83.4 |
| FY2024 | Dec 31, 2024 | -172.2% | −35.1 |
| FY2023 | Dec 31, 2023 | -137.1% | −47.2 |
| FY2022 | Dec 31, 2022 | -89.9% | +354.9 |
| FY2021 | Dec 31, 2021 | -444.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -32.0% | +43.6 |
| Q2 FY2026 | Jun 30, 2026 | -39.6% | +66.7 |
| Q1 FY2026 | Mar 31, 2026 | -51.5% | +930.1 |
| Q4 FY2025 | Dec 31, 2025 | -43.3% | +47.9 |
| Q3 FY2025 | Sep 30, 2025 | -75.6% | +20.1 |
| Q2 FY2025 | Jun 30, 2025 | -106.2% | +284.1 |
| Q1 FY2025 | Mar 31, 2025 | -981.7% | −835.4 |
| Q4 FY2024 | Dec 31, 2024 | -91.1% | +214.3 |
| Q3 FY2024 | Sep 30, 2024 | -95.7% | −88.0 |
| Q2 FY2024 | Jun 30, 2024 | -390.3% | −303.1 |
| Q1 FY2024 | Mar 31, 2024 | -146.3% | −29.8 |
| Q4 FY2023 | Dec 31, 2023 | -305.4% | −259.8 |
| Q3 FY2023 | Sep 30, 2023 | -7.7% | +96.8 |
| Q2 FY2023 | Jun 30, 2023 | -87.2% | +37.0 |
| Q1 FY2023 | Mar 31, 2023 | -116.5% | −11.5 |
| Q4 FY2022 | Dec 31, 2022 | -45.6% | +35.0 |
| Q3 FY2022 | Sep 30, 2022 | -104.6% | +27486.7 |
| Q2 FY2022 | Jun 30, 2022 | -124.2% | +29319.6 |
| Q1 FY2022 | Mar 31, 2022 | -105.0% | +28730.8 |
| Q4 FY2021 | Dec 31, 2021 | -80.6% | – |
| Q3 FY2021 | Sep 30, 2021 | -27591.3% | – |
| Q2 FY2021 | Jun 30, 2021 | -29443.8% | – |
| Q1 FY2021 | Mar 31, 2021 | -28835.7% | – |
See a number that looks wrong?